Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oral insulin
- Development stage
- Phase 3
- Lead developer
- Profil
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral
01
Overview
Oral insulin is an investigational pharmaceutical drug formulated as an oral capsule containing insulin (150 U) and 200 mg of 4-CNAB (N-(4-chlorosalicyloyl)-4-aminobutyrate). Developed by Profil Institut für Stoffwechselforschung GmbH, this formulation aims to provide an oral alternative to subcutaneous insulin injections for patients with type 2 diabetes. The inclusion of 4-CNAB, a permeation enhancer, is crucial for facilitating the absorption of insulin through the gastrointestinal tract, thereby enabling oral delivery.
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on Oral insulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oral insulin.